Publications
Role of gene dosage in the acquisition of antimony resistance in Leishmania donovani : experimental evidence Institute of Tropical Medicine
ISC1, a new Leishmania donovani population emerging in the Indian sub-continent: Vector competence of Phlebotomus argentipes Institute of Tropical Medicine University of Antwerp
Visceral leishmaniasis (VL), the most severe form of the disease, is caused by Leishmania donovani in the Indian sub-continent (ISC). Whole genome sequencing studies revealed that two parasite populations exist in the ISC: a main population named the Core Group (CG) found mostly in the lowlands, and a new, genetically different subpopulation called ISC1. Parasites belonging to the CG were shown to be responsible for the recent epidemics, ...
Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase Institute of Tropical Medicine
Leishmania protozoan parasites (Trypanosomatidae family) are the causative agents of cutaneous, mucocutaneous and visceral leishmaniasis worldwide. While these diseases are associated with significant morbidity and mortality, there are few adequate treatments available. Sterol 14alpha-demethylase (CYP51) in the parasite sterol biosynthesis pathway has been the focus of considerable interest as a novel drug target in Leishmania. However, its ...
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex Institute of Tropical Medicine
Spatial analysis of Leishmania donovani exposure in humans and domestic animals in a recent kala azar focus in Nepal Institute of Tropical Medicine
Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani Institute of Tropical Medicine University of Antwerp
Leishmania donovani is the causative agent of the potentially fatal disease visceral leishmaniasis (VL). Chemotherapeutic options available to treat VL are limited and often face parasite resistance, inconsistent efficacy, and toxic side effects. Paromomycin (PMM) was recently introduced to treat VL as a monotherapy and in combination therapy. It is vital to understand the mechanisms of PMM resistance to safeguard the drug. In the present ...